• Explore /
  • Poster
  • / Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.

Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.

Abstract Poster

Authors

null

Daniele Raggi

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Daniele Raggi , Patrizia Giannatempo , Luigi Mariani , Maurizio Colecchia , Giuseppina Calareso , Roberto Salvioni , Siraj Mahamed Ali , Jeffrey S. Ross , Jon Chung , Andrea Necchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Germ Cell/Testicular

Clinical Trial Registration Number

NCT03081923

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4547)

DOI

10.1200/JCO.2018.36.15_suppl.4547

Abstract #

4547

Poster Bd #

373

Abstract Disclosures

Similar Posters

First Author: Jeesun Yoon

First Author: David Tougeron

First Author: Viktor Grünwald

First Author: Enrique Grande